SCHEMBL1077207

SCHEMBL1077207

CC=Cc1c(C(N)=O)c2ccccc2n1-c1ccc(O)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.41
SRC P12931 1/20 0.41
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
POLB P06746 2/20 0.38
KLK7 P49862 1/20 0.38
GAA P10253 1/20 0.38
GFER P55789 1/20 0.38
HPGD P15428 2/20 0.37
LMNA P02545 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
USP14 P54578 4/20 0.37
THRB P10828 1/20 0.37
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
RORC P51449 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
CYP2C19 P33261 2/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30385663 1.00 EGFR (0.41) EGFRSRCMEN1KMT2APOLB
SCHEMBL1077205 1.00 EGFR (0.41) EGFRSRCMEN1KMT2APOLB
SCHEMBL1075588 0.88 GFER (0.47) EGFRMEN1KMT2APOLBKLK7
SCHEMBL1075587 0.88 GFER (0.47) EGFRMEN1KMT2APOLBKLK7
SCHEMBL2313630 0.88 GFER (0.47) EGFRMEN1KMT2APOLBKLK7
SCHEMBL1077236 0.86 EGFR (0.42) EGFRSRCMEN1KMT2APOLB
SCHEMBL30386742 0.86 EGFR (0.42) EGFRSRCMEN1KMT2APOLB
SCHEMBL16712352 0.81 PPARG (0.37) MEN1KMT2APOLBKLK7GAA
SCHEMBL1076223 0.80 EGFR (0.41) EGFRSRCKMT2APOLBGAA
SCHEMBL1076224 0.80 EGFR (0.41) EGFRSRCKMT2APOLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2276732-B1 NOVEL ESTROGEN RECEPTOR LIGANDS KAROBIO AB (SE) 2015-05-20 EP disclosed
US-8367665-B2 Estrogen receptor ligands KARO BIO AB (SE) 2013-02-05 US disclosed
US-20110190294-A1 NOVEL ESTROGEN RECEPTOR LIGANDS OASMIA PHARMACEUTICAL AB (SE) 2011-08-04 US disclosed
EP-2276732-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-01-26 EP disclosed
WO-2009127686-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190294-A1 NOVEL ESTROGEN RECEPTOR LIGANDS ESR1, GPER1, ESRRA EGFR 69/4885SRC 1202/4885MEN1 1997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.